Research programme: monoclonal antibodies - Incyte/Medarex
Latest Information Update: 19 Sep 2006
At a glance
- Originator Incyte Corporation; Medarex
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 19 Sep 2006 Discontinued - Preclinical for undisclosed indication in USA (unspecified route)
- 29 Jun 2005 This programme is still in active development
- 30 Apr 2003 Incyte Genomics is now called Incyte Corporation